GlaxoSmithKline: IMPACT Study Shows Benefits Of Trelegy Ellipta In COPD Patients

[unable to retrieve full-text content]

GlaxoSmithKline: IMPACT Study Shows Benefits Of Trelegy Ellipta In COPD Patients  Nasdaq GlaxoSmithKline IMPACT study shows significant benefits of Trelegy Ellipta for COPD patients  Stock Market Wire Full coverage

https://www.nasdaq.com/article/glaxosmithkline-impact-study-shows-benefits-of-trelegy-ellipta-in-copd-patients-20180419-00077